Interview

'Your diagnostic is only as good as what you understand about a disease'

5 questions with Renee Yura
Laurel Oldach
October 30, 2020

Pfizer diagnostic expert Renee Yura oversees diagnostic test development that helps target drugs to the people who will benefit most from them — and this year she has been hard at work supporting Pfizer’s COVID-19 response. Yura, who recently joined the American Society for Biochemistry and Molecular Biology Membership Committee, carved out some time to tell ASBMB Today about her work. This interview has been condensed and edited.

Yura-Renee-445x529.jpg

Name: Renee Yura

Current position: Director, nononcology diagnostics, Pfizer

Degree: Ph.D., Pennsylvania State University School of Medicine, 2008

First job outside of academia: Scientist I, Johnson & Johnson

Favorite molecule or protein: Meprin, which reminds her of graduate school. “It’s funny that you could have nostalgia for a protein.”

What do you do as a team lead in diagnostics?

We are responsible to meet diagnostic needs for different drug programs at Pfizer. Personalized medicine has become more and more common; if you develop a drug that will only work for certain patients, you need a diagnostic test that will reliably identify those patients. When a test is considered essential for the safe use of a drug, it’s called a companion diagnostic, and how it’s developed is really important. It has phases similar to the drug development process

Do you often simultaneously develop a test and a therapy?

That’s the ideal path for a companion diagnostic. Ideally, when you take a drug into a first-in-human study, you have an idea of the biomarker you’d like to translate into a diagnostic and a guess about how much of it you need in someone’s serum for them to respond properly to a drug. That’s a hypothesis you’ll go in with, and then you see if it holds true as you generate clinical trial data.

Is there a project that you’re especially proud to have worked on?

Anytime anything comes to market, it’s super exciting — for every one thing that comes to market, there are five that don’t.

One thing that I was really excited to work on early in my career was developing a polymerase chain reaction panel for several respiratory pathogens. Now, in the age of SARS-CoV-2, that serves me well. Pfizer has a range of work going on in the vaccine and treatment space, and it’s critical to understand the quality metrics around the diagnostics on the market right now.

I’ve heard people say COVID-19 diagnostics don’t work. A lot of them actually should work very, very well; the thing is, your diagnostic is only as good as what you understand about a disease. If you’re collecting the wrong sample, or collecting it too early or too late, the best diagnostic test in the world might give an incorrect result.

What got you interested in diagnostics?

I got into it by chance. I graduated in 2008 — the economy was horrible at that time. I kept applying for jobs and thought, “What’s wrong with me?” because no one was biting.

Through a friend of a friend, I heard about a three-month contracting position at Johnson & Johnson. I just jumped at it. I mean, I would have taken a job scrubbing the floors at Johnson & Johnson! The three-month contract turned into a one-year contract, which turned into a permanent position. It happened to be in the diagnostics department.

Anything you wish you’d known about working in industry?

People don’t realize that there are a lot of ways to be close to the science without having to do the science. You can do patient advocacy, or commercial work, or you can get a law degree and then do patent law for a pharmaceutical company. I didn’t know that 90% of those jobs existed until I moved into industry. I think if people had access to that information earlier, it would help them plan better.

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in People

People highlights or most popular articles

James Siedow (1947–2020)
Retrospective

James Siedow (1947–2020)

November 30, 2020

The former Duke University administrator and plant researcher is remembered for his leadership, discoveries and kindness.

Targeting two-faced nuclear receptors to fight cancer
News

Targeting two-faced nuclear receptors to fight cancer

November 24, 2020

For small-molecule cancer drugs, context is everything. Drugs that ameliorate cancer in some tissues may increase the cancer risk in others. Researcher Stephen Safe has turned this challenge into an opportunity.

Gerald S. Berenson (1922–2018)
Retrospective

Gerald S. Berenson (1922–2018)

November 23, 2020

A physician–scientist who devoted more than six decades to understanding the causes of cardiovascular disease, Berenson was one of the earliest members of the American Society for Biochemistry and Molecular Biology.

Collins, Kim and Qian receive Pioneer grants; McKnight wins Welch award; remembering Donald Comb
Member News

Collins, Kim and Qian receive Pioneer grants; McKnight wins Welch award; remembering Donald Comb

November 23, 2020

Awards, promotions, milestones and more. Find out what's going on in the lives of ASBMB members.

ASBMB welcomes new members
Member News

ASBMB welcomes new members

November 23, 2020

The American Society for Biochemistry and Molecular Biology welcomed more than 140 new members in July.

“You’ve got … to get outside of your comfort zone”
Interview

“You’ve got … to get outside of your comfort zone”

November 20, 2020

Wayne Fairbrother leads a department at Genentech tasked with validating disease-associated targets and determining whether they could be feasible for drug development.